Belinda Cowling

Belinda Cowling

CSO

Belinda Cowling’s (PhD, Chief Scientific Officer) research at the IGBMC (Strasbourg) led to the creation of Dynacure in 2016, of which she is cofounder and was scientific advisor. Belinda is responsible for the company’s R&D strategy, and leading Dynacure’s research programs in centronuclear myopathy (CNM) and other disease domains. Her focus is on translational research, drug-candidate development and expanding Dynacure’s research network with academic and industrial partners. Belinda completed her PhD in Australia at Monash University in 2008. She then moved to the IGBMC, France, to complete a postdoc in the team of Dr. Jocelyn Laporte, where  she studied the normal biological function of dynamin 2. She identified down regulation of this gene as a novel therapeutic target for centronuclear myopathies1,2. She has more than 15 years’ experience in neuromuscular disease research and has published more than 28 publications in peer-reviewed journals.

1Tasfaout H, Buono S, Guo S, Kretz C, Messaddeq N, Booten S, Greenlee S, Monia BP, Cowling BS*, Laporte J*. Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice. Nat Commun. 2017 Jun 7;8:15661. *equal last and corresponding authors
2Buono S, Buono S, Ross JA, Tasfaout H, Levy Y, Kretz C, Tayefeh L, Matson J, Guo S, Kessler P, Monia BP, Bitoun M, Ochala J, Laporte J, Cowling BS. Reducing dynamin  2 (DNM2) rescues DNM2-related dominant centronuclear myopathy. Proc Natl Acad Sci U S A. 2018 Oct 23;115(43):11066-11071.